Development of Dl1.72, a Novel Anti-DLL1 Antibody with Anti-Tumor Efficacy against Estrogen Receptor-Positive Breast Cancer

SIMPLE SUMMARY: Over 70% of breast cancers (BCs) are estrogen receptor-positive (ER(+)). The development of endocrine therapy has considerably improved patient outcomes. However, there is a clinical need for novel effective therapies against ER(+) BCs, since many of these do not respond to standard...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Gabriela, Sales-Dias, Joana, Casal, Diogo, Alves, Sara, Domenici, Giacomo, Barreto, Clara, Matos, Carolina, Lemos, Ana R., Matias, Ana T., Kucheryava, Khrystyna, Ferreira, Andreia, Moita, Maria Raquel, Braga, Sofia, Brito, Catarina, Cabral, M. Guadalupe, Casalou, Cristina, Barral, Duarte C., Sousa, Pedro M. F., Videira, Paula A., Bandeiras, Tiago M., Barbas, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392387/
https://www.ncbi.nlm.nih.gov/pubmed/34439228
http://dx.doi.org/10.3390/cancers13164074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392387/
https://www.ncbi.nlm.nih.gov/pubmed/34439228
http://dx.doi.org/10.3390/cancers13164074

Ejemplares similares